Showing results (321-330 of 447) with videos related to

Sort By:
Pageof 45
Headache|December 28, 2021
Development and validation of a novel patient-reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine DiaryRichard B Lipton, Pranav Gandhi, Jonathan Stokes, et al.
European Journal of Neurology|January 5, 2021
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trialMessoud Ashina, Peter J Goadsby, Uwe Reuter, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|May 1, 2022
Sleep restriction alters cortical inhibition in migraine: A transcranial magnetic stimulation studyMartin Syvertsen Mykland, Martin Uglem, Jan Petter Neverdahl, et al.
Headache|June 2, 2019
Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized TrialsStewart J Tepper, John H Krege, Louise Lombard, et al.
Headache|October 27, 2018
Improving Medical Communication in Migraine Management: A Modified Delphi Study to Develop a Digital Migraine TrackerDavid W Dodick, Stewart J Tepper, Richard B Lipton, et al.
JAMA|May 26, 2018
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical TrialDavid W Dodick, Stephen D Silberstein, Marcelo E Bigal, et al.
Nature Reviews. Disease Primers|January 14, 2022
MigraineMichel D Ferrari, Peter J Goadsby, Rami Burstein, et al.
Lancet (London, England)|November 18, 2023
Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USADavid W Dodick, Peter J Goadsby, Todd J Schwedt, et al.
Headache|September 30, 2021
Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing dataDavid W Dodick, Stewart J Tepper, Jessica Ailani, et al.
Headache|February 20, 2020
Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and IIDavid W Dodick, Richard B Lipton, Jessica Ailani, et al.
Pageof 45